Diversity in Clinical Trials – How to Attain It?
All agree that ethnic groups are massively under-represented when it comes to clinical trials, and although barriers to diversity in…
eTMF Best Practice for a Lean Team
The TMF is the official record of the clinical study for Regulatory Authorities, be it the FDA, Health Canada, or…
Canada: For Your Phase 3 Global Trial Expansion
Oncology continues to be the largest and fastest growing therapeutic area in the clinical trials market, and a market dominated…
Doubly Nimble: why you should open global P1 clinical trials in Canada on Day 1
With agility increasingly becoming the most important global driver of success, it’s worth noting that Canadian oncology research center Phase…
What’s Best for Your Phase III Clinical Study?
It’s worth your time to consider whether or not the commonly held belief that using a larger CRO for your…
Troubleshooting Underperforming Sites – Best Practices
It’s no surprise that an underperforming site can cause significant delays in meeting important accrual targets, data timelines, or study…
Special Report: What’s in Store for Global Clinical Trials in 2022 and Beyond?
The Global Clinical Trials Market was valued at $44.3B USD in 2020, and by 2028 is expected to reach $69.3B…
Prime Location for Global Clinical Studies?
Canada is considered one of the most attractive places to live in the world, with a high quality of life,…
What & Where: the ‘Next Normal’ in Oncology Clinical Research
Developing oncology compounds is a constantly evolving process, and never more so than now. Pre-pandemic oncology was both the largest…
Why Not Canada for Your Phase 3 Global Trial Expansion?
Pre-pandemic oncology was both the largest and fastest growing therapeutic area in the clinical trials market. A key market trend…